Heim22UA • FRA
add
BioNTech SE - ADR
Við síðustu lokun
90,95 €
Dagbil
90,20 € - 92,85 €
Árabil
69,70 € - 124,60 €
Markaðsvirði
24,05 ma. USD
Meðalmagn
811,00
V/H-hlutf.
-
A/V-hlutfall
-
Aðalkauphöll
NASDAQ
Í fréttum
Fjármál
Rekstrarreikningur
Tekjur
Nettótekjur
| (EUR) | des. 2024info | Breyting á/á |
|---|---|---|
Tekjur | 1,19 ma. | -19,54% |
Rekstrarkostnaður | 816,80 m. | 15,68% |
Nettótekjur | 259,50 m. | -43,33% |
Hagnaðarhlutfall | 21,81 | -29,55% |
Hagnaður á hvern hlut | 1,08 | -43,16% |
EBITDA | 295,10 m. | -52,96% |
Virkt skatthlutfall | 13,84% | — |
Efnahagsreikningur
Heildareignir
Heildarskuldir
| (EUR) | des. 2024info | Breyting á/á |
|---|---|---|
Reiðufé og skammtímafjárfestingar | 16,78 ma. | 1,42% |
Heildareignir | 22,53 ma. | -2,07% |
Heildarskuldir | 3,12 ma. | 12,98% |
Eigið fé alls | 19,41 ma. | — |
Útistandandi hlutabréf | 240,28 m. | — |
Eiginfjárgengi | 1,13 | — |
Arðsemi eigna | 1,44% | — |
Ávöxtun eigin fjár | 1,66% | — |
Peningaflæði
Breyting á handbæru fé
| (EUR) | des. 2024info | Breyting á/á |
|---|---|---|
Nettótekjur | 259,50 m. | -43,33% |
Handbært fé frá rekstri | -463,30 m. | -154,45% |
Reiðufé frá fjárfestingum | 606,70 m. | 122,51% |
Reiðufé frá fjármögnun | -7,30 m. | 43,41% |
Breyting á handbæru fé | 137,30 m. | 107,49% |
Frjálst peningaflæði | -174,31 m. | -130,65% |
Um
BioNTech SE is a global biotechnology company headquartered in Mainz that develops immunotherapies and vaccines, particularly for cancer and infectious diseases.
The company utilizes technology platforms including mRNA-based therapies, targeted therapies, and immunomodulators, to develop its treatments. BioNTech's pipeline includes several late-stage programs in oncology testing combination therapy approaches to improve treatment outcomes.
In the field of infectious diseases, BioNTech, partnering with Pfizer, developed Comirnaty, the first approved mRNA-based vaccine, which was widely used during the COVID-19 pandemic. Wikipedia
Framkvæmdastjóri
Stofnsett
2008
Vefsvæði
Starfsfólk
6.772
